PSTX Poseida Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PSTX

Price (delayed)

$2.84

Market cap

$274.03M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.37

Enterprise value

$314.98M

Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. Poseida ...

Highlights
Poseida Therapeutics's debt has decreased by 3.8% YoY
Poseida Therapeutics's net income has plunged by 93% YoY but it has increased by 6% from the previous quarter
PSTX's EPS has shrunk by 54% YoY but it is up by 12% QoQ
Poseida Therapeutics's equity has decreased by 45% YoY and by 16% QoQ
The quick ratio has declined by 43% year-on-year and by 3.7% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://poseida.com
Peers: OMER OMGA

Key stats

What are the main financial stats of PSTX
Market
Shares outstanding
96.49M
Market cap
$274.03M
Enterprise value
$314.98M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.62
Price to sales (P/S)
3.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.87
Earnings
Revenue
$64.7M
EBIT
-$114.65M
EBITDA
-$109.04M
Free cash flow
-$95.23M
Per share
EPS
-$1.37
Free cash flow per share
-$1.06
Book value per share
$1.08
Revenue per share
$0.72
TBVPS
$2.98
Balance sheet
Total assets
$273.89M
Total liabilities
$170.18M
Debt
$85.42M
Equity
$103.7M
Working capital
$155.16M
Liquidity
Debt to equity
0.82
Current ratio
3.18
Quick ratio
3.1
Net debt/EBITDA
-0.38
Margins
EBITDA margin
-168.5%
Gross margin
100%
Net margin
-190.8%
Operating margin
-200.2%
Efficiency
Return on assets
-42.2%
Return on equity
-94.9%
Return on invested capital
-42.1%
Return on capital employed
-56.6%
Return on sales
-177.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PSTX stock price

How has the Poseida Therapeutics stock price performed over time
Intraday
1.79%
1 week
33.33%
1 month
-7.19%
1 year
4.41%
YTD
-15.48%
QTD
-10.97%

Financial performance

How have Poseida Therapeutics's revenue and profit performed over time
Revenue
$64.7M
Gross profit
$64.7M
Operating income
-$129.5M
Net income
-$123.43M
Gross margin
100%
Net margin
-190.8%
The operating income has dropped by 116% year-on-year but it is up by 5% since the previous quarter
Poseida Therapeutics's net income has plunged by 93% YoY but it has increased by 6% from the previous quarter
The revenue has plunged by 50% YoY but it has grown by 30% from the previous quarter
The gross profit has plunged by 50% YoY but it has grown by 30% from the previous quarter

Growth

What is Poseida Therapeutics's growth rate over time

Valuation

What is Poseida Therapeutics stock price valuation
P/E
N/A
P/B
2.62
P/S
3.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.87
PSTX's EPS has shrunk by 54% YoY but it is up by 12% QoQ
Poseida Therapeutics's equity has decreased by 45% YoY and by 16% QoQ
The P/B is 35% more than the last 4 quarters average of 1.9
The revenue has plunged by 50% YoY but it has grown by 30% from the previous quarter
The stock's price to sales (P/S) is 30% more than its last 4 quarters average of 3.0

Efficiency

How efficient is Poseida Therapeutics business performance
PSTX's ROE has dropped by 113% year-on-year and by 9% since the previous quarter
PSTX's ROA has dropped by 95% year-on-year
The ROIC has shrunk by 57% YoY
PSTX's ROS is up by 28% QoQ

Dividends

What is PSTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PSTX.

Financial health

How did Poseida Therapeutics financials performed over time
The total assets is 61% more than the total liabilities
The current ratio has contracted by 43% YoY and by 3% from the previous quarter
The quick ratio has declined by 43% year-on-year and by 3.7% since the previous quarter
Poseida Therapeutics's debt is 18% lower than its equity
Poseida Therapeutics's debt to equity has surged by 74% YoY and by 17% QoQ
Poseida Therapeutics's equity has decreased by 45% YoY and by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.